TY - JOUR
T1 - PCM4EU and PRIME-ROSE
T2 - Collaboration for implementation of precision cancer medicine in Europe
AU - Taskén, Kjetil
AU - F Haj Mohammad, Soemeya
AU - Fagereng, Gro Live
AU - PRIME-ROSE Consortium and the PCM4EU Consortium
AU - Sørum Falk, Ragnhild
AU - Helland, Åslaug
AU - Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar
AU - Steen Carlsson, Katarina
AU - Ryll, Bettina
AU - Jalkanen, Katriina
AU - Edsjö, Anders
AU - Russnes, Hege G.
AU - Lassen, Ulrik
AU - Hallersjö Hult, Ebba
AU - Lugowska, Iwona
AU - Blay, Jean Yves
AU - Verlingue, Loic
AU - Abel, Edvard
AU - Lowery, Maeve A.
AU - Krebs, Matthew G.
AU - Staal Rohrberg, Kristoffer
AU - Ojamaa, Kristiina
AU - Oliveira, Julio
AU - Verheul, Henk M.W.
AU - Voest, Emile E.
AU - Gelderblom, Hans
N1 - Publisher Copyright:
© 2024 The Author(s). Published by MJS Publishing on behalf of Acta Oncologica.
PY - 2024/5/23
Y1 - 2024/5/23
N2 - Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful. Patients and methods: PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe. Results: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu. eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. Conclusion: European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.
AB - Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful. Patients and methods: PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe. Results: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu. eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. Conclusion: European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.
UR - http://www.scopus.com/inward/record.url?scp=85194016443&partnerID=8YFLogxK
U2 - 10.2340/1651-226X.2024.34791
DO - 10.2340/1651-226X.2024.34791
M3 - Article
C2 - 38779910
AN - SCOPUS:85194016443
SN - 0284-186X
VL - 63
SP - 385
EP - 391
JO - Acta oncologica (Stockholm, Sweden)
JF - Acta oncologica (Stockholm, Sweden)
ER -
